Rankia México
Acceder
¿Nos visitas desde USA? Entra a tu página Rankia.us.

Farmas USA

115243 respuestas
    Kurdt
    #115129

    Re: Farmas USA

    Ver mensaje de lgonber

    Es que no tiene sentido que lo traten como un dividendo. Imagínate el BO de Celg y BMY, por 1 acción de Celg te dan 50$ en efectivo y 1 acción de BMY. Alguien que tenga Celg compradas a 120-130 aun seguiría en pérdidas a día de hoy, como le van a descontar un 15% como si fuera un dividendo en la parte en efectivo? No se si me explico bien ya que estoy en modo móvil o yo no me estoy enterando por el mismo motivo.

  1. framus_morrigan
    #115132

    Re: Farmas USA

    TGTX ahí va el breakout del iHCH comentado

     

    REGN en semanal por ahora … con todo el verde que se ha visto … que le pasa a esta pajara? esta muy débil ...

     

  2. anaramos
    #115133

    Re: Farmas USA

     

    MLNT

    Disparada en pre.

    U.S. Food and Drug Administration (FDA) has accepted a
    supplemental New Drug Application (sNDA) for BAXDELA(®) (delafloxacin) for
    priority review. The sNDA filing seeks to expand the current indication for
    BAXDELA to include adult patients with community-acquired bacterial pneumonia
    (CABP).

    The FDA granted priority review status based on the previous Qualified
    Infectious Disease Product (QIDP) designation, which provides certain
    incentives for the development of antibacterial and antifungal treatments for
    serious or life-threatening infections. Through this process, the FDA has
    assigned a Prescription Drug User Fee Act (PDUFA) action date (proposed review
    deadline) of October 24, 2019.

    "Due to the rise of antibiotic resistance and an aging population,
    community-acquired bacterial pneumonia, or CABP, remains a challenge for
    healthcare professionals and has led to a need for new treatment options,”
    said Sue Cammarata, M.D., chief medical officer of Melinta. "BAXDELA’s
    potency and activity against the most common bacterial pathogens seen in CABP
    indicate it could play a significant role in the treatment of this
    life-threatening illness, if approved. We look forward to working with the FDA
    to help evaluate bringing this potential option to people with CABP as soon as
    possible.”

    The sNDA application is based on positive results from a Phase III,
    randomized, double-blind, study that compared the efficacy and safety of
    BAXDELA to moxifloxacin for the treatment of CABP. The study results showed
    that BAXDELA had comparable efficacy to moxifloxacin for early clinical
    response and clinical outcome at test of cure. Additionally, BAXDELA was
    generally safe and well-tolerated. Detailed efficacy and safety results from
    this study will be submitted for presentation at an upcoming medical
    conference.

    BAXDELA was approved by the FDA in 2017 for the treatment of adult patients
    with acute bacterial skin and skin structure infections (ABSSSI) caused by
    designated susceptible bacteria.

  3. Zokatira96
    #115135

    Re: Farmas USA

    Ver mensaje de mugiwara

    MLNT 

    Su problema sigue siendo financiero por pobres ventas y grandes gastos de maneras que esa noticia solo abre expectativas no genera resultados, creo que en poco se va desinflar ,aunque veo ha tocado 4 + 100 % en pre

    Tiene  52 Week Range 1.62 - 42.7     si presenta un mejor Q2/er 2019 tal vez empieze una reversion de la  t bajista que lleva 2 años ya 

    Gracias por avisar Ana

Brokers destacados

¿Aún no eres usuario de Rankia?

Somos más de 1.050.000 usuarios

Regístrate y podrás:

  • Guardarte contenidos y usuarios
  • Participar en promociones especiales
  • Publicar mensajes en Foros y Opiniones
  • Participar en el Juego de Bolsa